Key Events This Week
Feb 09: Stock opens at Rs.1,166.60, modest gain amid Sensex rise
Feb 10: Sharp dip to Rs.1,137.20 on heavy volume
Feb 11: Recovery to Rs.1,147.50 with moderate volume
Feb 12: New 52-week and all-time highs at Rs.1,242.15 and Rs.1,235 respectively, strong quarterly results announced
Feb 13: Stock hits fresh 52-week high of Rs.1,425 and all-time high of Rs.1,410, closing at Rs.1,431.20
Monday, 9 February 2026: Modest Start Amid Broad Market Gains
Kwality Pharmaceuticals opened the week at Rs.1,166.60, gaining 0.77% on the day with a volume of 6,078 shares. This modest rise came alongside a 1.04% gain in the Sensex, which closed at 37,113.23. The stock’s performance was in line with the broader market optimism, setting a positive tone for the week ahead.
Tuesday, 10 February 2026: Sharp Decline on Heavy Volume
The stock experienced a notable setback on 10 February, falling 2.52% to Rs.1,137.20 on significantly higher volume of 24,221 shares. Despite the Sensex advancing 0.25% to 37,207.34, Kwality Pharmaceuticals underperformed, suggesting profit-taking or sector-specific pressures. This dip was short-lived as the stock rebounded the following day.
Wednesday, 11 February 2026: Recovery Gains Amid Moderate Volume
On 11 February, the stock recovered 0.91% to close at Rs.1,147.50 with volume of 8,507 shares. The Sensex posted a smaller gain of 0.13%, closing at 37,256.72. This recovery indicated renewed buying interest ahead of the company’s quarterly results and upcoming price milestones.
Thursday, 12 February 2026: Breakout to New 52-Week and All-Time Highs
Kwality Pharmaceuticals surged dramatically on 12 February, hitting a new 52-week high of Rs.1,242.15 and an all-time high of Rs.1,235 during the session. The stock closed at Rs.1,362.00, up 18.69% on massive volume of 251,784 shares, vastly outperforming the Sensex which declined 0.56% to 37,049.40. This breakout was supported by the company’s strong Q3 FY26 results, which revealed a 66.9% net profit growth and margin expansion, signalling operational strength and robust financial health.
The stock’s rally was further bolstered by its trading above all key moving averages, confirming a strong bullish trend. The company’s mojo grade was upgraded from Hold to Buy on 29 January 2026, reflecting improved fundamentals and market sentiment.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Friday, 13 February 2026: New Peaks Amid Volatility and Strong Financials
The momentum continued on 13 February as Kwality Pharmaceuticals hit a fresh 52-week high of Rs.1,425 and an all-time high of Rs.1,410 intraday. Despite intraday volatility with a low of Rs.1,321.10, the stock closed at Rs.1,431.20, up 5.08% on volume of 182,350 shares. This represented a 3.80% gain on the day, outperforming the Sensex’s 1.40% decline to 36,532.48.
The company’s financial metrics remained robust, with an 87.79% net profit growth in the December 2025 quarter, eight consecutive quarters of positive results, and a high return on capital employed (ROCE) of 19.03%. Operational efficiency was highlighted by an inventory turnover ratio of 5.04 times and an operating profit to interest coverage ratio of 12.08 times, underscoring strong earnings quality and debt servicing capacity.
Valuation metrics shifted to an ‘expensive’ rating with a P/E ratio of 24.73 and P/BV of 4.87, reflecting premium pricing. However, the low PEG ratio of 0.38 suggests that earnings growth supports this valuation. Notably, domestic mutual funds hold no stake in the company, indicating a cautious institutional stance despite the strong market performance.
Curious about Kwality Pharmaceuticals Ltd from ? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Daily Price Comparison: Kwality Pharmaceuticals vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-02-09 | Rs.1,166.60 | +0.77% | 37,113.23 | +1.04% |
| 2026-02-10 | Rs.1,137.20 | -2.52% | 37,207.34 | +0.25% |
| 2026-02-11 | Rs.1,147.50 | +0.91% | 37,256.72 | +0.13% |
| 2026-02-12 | Rs.1,362.00 | +18.69% | 37,049.40 | -0.56% |
| 2026-02-13 | Rs.1,431.20 | +5.08% | 36,532.48 | -1.40% |
Key Takeaways
Strong Outperformance: Kwality Pharmaceuticals surged 23.63% over the week, vastly outperforming the Sensex’s 0.54% decline, highlighting exceptional relative strength.
Record Highs and Momentum: The stock set multiple 52-week and all-time highs, closing at Rs.1,431.20 on 13 February, supported by strong technicals and sustained buying interest.
Robust Financials: The company reported an 87.79% net profit growth in Q3 FY26, with eight consecutive quarters of positive results, margin expansion, and efficient capital utilisation (ROCE 19.03%).
Valuation Shift: The stock’s valuation moved from fair to expensive with a P/E of 24.73 and P/BV of 4.87, though a low PEG ratio of 0.38 suggests earnings growth supports the premium.
Institutional Caution: Domestic mutual funds hold no stake, indicating a cautious stance despite strong fundamentals and market performance.
Volume and Volatility: The rally was accompanied by significant volume spikes and intraday volatility, reflecting active trading and investor interest.
Mojo Grade Upgrade: The mojo grade upgrade from Hold to Buy with a score of 77.0 reflects improved market sentiment and fundamental strength.
Conclusion
Kwality Pharmaceuticals Ltd’s week was characterised by a powerful rally driven by strong quarterly results, multiple new highs, and a mojo grade upgrade signalling enhanced investor confidence. The stock’s 23.63% gain sharply outpaced the Sensex’s decline, underscoring its robust market position and operational excellence. While valuation metrics suggest a premium pricing environment, the company’s solid earnings growth and efficient capital management provide a strong foundation for this elevated level. Institutional caution remains a factor to watch, but the stock’s sustained momentum and financial strength mark this week as a significant milestone in its market journey.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
